Zobrazeno 1 - 10 of 531 pro vyhledávání: '"Arrate MP"'
1
Akademický článek
TLR3 agonism augments CD47 inhibition in acute myeloid leukemia.
Autor: Ramsey HE; Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN; Program in Cancer Biology., Gorska AE; Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN., Smith BN; Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN., Monteith AJ; Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN., Fuller L; Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN., Arrate MP; Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN., Savona MR; Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN; Center for Immunobiology; Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN. michael.savona@vanderbilt.edu.
Publikováno v: Haematologica [Haematologica] 2024 Jul 01; Vol. 109 (7), pp. 2111-2121. Date of Electronic Publication: 2024 Jul 01.
Zobrazit plný text záznamu
2
Akademický článek
Lactate Utilization Enables Metabolic Escape to Confer Resistance to BET Inhibition in Acute Myeloid Leukemia.
Autor: Monteith AJ; Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee.; Cancer Biology Program, Vanderbilt University School of Medicine, Nashville, Tennessee.; Department of Microbiology, University of Tennessee, Knoxville, Tennessee., Ramsey HE; Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee.; Cancer Biology Program, Vanderbilt University School of Medicine, Nashville, Tennessee., Silver AJ; Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee.; Cancer Biology Program, Vanderbilt University School of Medicine, Nashville, Tennessee., Brown D; Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee., Greenwood D; Department of Pathology, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee., Smith BN; Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee.; Cancer Biology Program, Vanderbilt University School of Medicine, Nashville, Tennessee., Wise AD; Department of Microbiology, University of Tennessee, Knoxville, Tennessee., Liu J; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina., Olmstead SD; Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee., Watke J; Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee., Arrate MP; Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee., Gorska AE; Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee., Fuller L; Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee., Locasale JW; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina., Stubbs MC; Incyte Corporation, Wilmington, Delaware., Rathmell JC; Cancer Biology Program, Vanderbilt University School of Medicine, Nashville, Tennessee.; Department of Pathology, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee.; Vanderbilt Center for Immunobiology, Vanderbilt University School of Medicine, Nashville, Tennessee.; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee., Savona MR; Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee.; Cancer Biology Program, Vanderbilt University School of Medicine, Nashville, Tennessee.; Vanderbilt Center for Immunobiology, Vanderbilt University School of Medicine, Nashville, Tennessee.; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
Publikováno v: Cancer research [Cancer Res] 2024 Apr 01; Vol. 84 (7), pp. 1101-1114.
Zobrazit plný text záznamu
3
Akademický článek
BET Inhibition Enhances the Antileukemic Activity of Low-dose Venetoclax in Acute Myeloid Leukemia.
Autor: Ramsey HE; Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee.; Cancer Biology Program, Vanderbilt University School of Medicine, Nashville, Tennessee., Greenwood D; Department of Pathology, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee., Zhang S; Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee., Childress M; Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee., Arrate MP; Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee., Gorska AE; Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee., Fuller L; Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee., Zhao Y; Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee., Stengel K; Department of Pathology, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee., Fischer MA; Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee.; Cancer Biology Program, Vanderbilt University School of Medicine, Nashville, Tennessee., Stubbs MC; Incyte Corporation, Wilmington, Delaware., Liu PCC; Incyte Corporation, Wilmington, Delaware., Boyd K; Department of Pathology, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee., Rathmell JC; Cancer Biology Program, Vanderbilt University School of Medicine, Nashville, Tennessee.; Department of Pathology, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee.; Vanderbilt Center for Immunobiology, Nashville, Tennessee.; Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee., Hiebert SW; Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee.; Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee., Savona MR; Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee. michael.savona@vumc.org.; Cancer Biology Program, Vanderbilt University School of Medicine, Nashville, Tennessee.; Vanderbilt Center for Immunobiology, Nashville, Tennessee.; Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee.
Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Jan 15; Vol. 27 (2), pp. 598-607. Date of Electronic Publication: 2020 Nov 04.
Zobrazit plný text záznamu
4
Akademický článek
Selective inhibition of MCL1 overcomes venetoclax resistance in a murine model of myelodysplastic syndromes.
Autor: Fischer MA; Department of Medicine; Cancer Biology Program, Vanderbilt University School of Medicine., Song Y; Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China; Smilow Cancer Center, Yale University School of Medicine, New Haven., Arrate MP; Department of Medicine., Gbyli R; Smilow Cancer Center, Yale University School of Medicine, New Haven., Villaume MT; Department of Medicine; Cancer Biology Program, Vanderbilt University School of Medicine., Smith BN; Department of Medicine; Cancer Biology Program, Vanderbilt University School of Medicine; Department of Pediatrics., Childress MA; Department of Medicine; Cancer Biology Program, Vanderbilt University School of Medicine., Stricker TP; Vanderbilt-Ingram Cancer Center; Department of Pathology, Microbiology, and Immunology., Halene S; Smilow Cancer Center, Yale University School of Medicine, New Haven., Savona MR; Department of Medicine; Cancer Biology Program, Vanderbilt University School of Medicine; Vanderbilt-Ingram Cancer Center; Center for Immunobiology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232. michael.savona@vanderbilt.edu.
Publikováno v: Haematologica [Haematologica] 2023 Feb 01; Vol. 108 (2), pp. 522-531. Date of Electronic Publication: 2023 Feb 01.
Zobrazit plný text záznamu
5
Akademický článek
Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia.
Autor: Cojocari D; Oncology Discovery, AbbVie, Inc., Smith BN; Department of Pediatrics; Medicine; Program in Cancer Biology, Vanderbilt University School of Medicine., Purkal JJ; Oncology Discovery, AbbVie, Inc., Arrate MP; Medicine., Huska JD; Oncology Discovery, AbbVie, Inc., Xiao Y; Oncology Discovery, AbbVie, Inc., Gorska A; Medicine., Hogdal LJ; Precision Medicine, AbbVie Inc., 1 North Waukegan Rd., North Chicago, IL 60064., Ramsey HE; Medicine; Program in Cancer Biology, Vanderbilt University School of Medicine., Boghaert ER; Oncology Discovery, AbbVie, Inc., Phillips DC; Oncology Discovery, AbbVie, Inc., Savona MR; Medicine; Program in Cancer Biology, Vanderbilt University School of Medicine; Vanderbilt-Ingram Cancer Center; Center for Immunobiology, Vanderbilt University School of Medicine, Nashville, TN 37232. michael.savona@vanderbilt.edu.
Publikováno v: Haematologica [Haematologica] 2022 Apr 01; Vol. 107 (4), pp. 825-835. Date of Electronic Publication: 2022 Apr 01.
Zobrazit plný text záznamu
6
Akademický článek
The delta isoform of phosphatidylinositol-3-kinase predominates in chronic myelomonocytic leukemia and can be targeted effectively with umbralisib and ruxolitinib.
Autor: Villaume MT; Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN; Program in Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN., Arrate MP; Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN., Ramsey HE; Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN; Program in Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN., Sunthankar KI; Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN., Jenkins MT; Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN; Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN., Moyo TK; Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN., Smith BN; Program in Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN; Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN., Fischer MA; Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN; Program in Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN., Childress MA; Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN; Program in Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN., Gorska AE; Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN., Ferrell PB; Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN; Program in Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN; Center for Immunobiology, Vanderbilt University School of Medicine, Nashville, TN; Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN., Savona MR; Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN; Program in Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN; Center for Immunobiology, Vanderbilt University School of Medicine, Nashville, TN; Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN. Electronic address: michael.savona@vanderbilt.edu.
Publikováno v: Experimental hematology [Exp Hematol] 2021 May; Vol. 97, pp. 57-65.e5. Date of Electronic Publication: 2021 Feb 19.
Zobrazit plný text záznamu
7
Akademický článek
Venetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic malignancies.
Autor: Fischer MA; Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN., Friedlander SY; Karyopharm Therapeutics Inc., Newton, MA; and., Arrate MP; Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN., Chang H; Karyopharm Therapeutics Inc., Newton, MA; and., Gorska AE; Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN., Fuller LD; Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN., Ramsey HE; Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN., Kashyap T; Karyopharm Therapeutics Inc., Newton, MA; and., Argueta C; Karyopharm Therapeutics Inc., Newton, MA; and., Debler S; Karyopharm Therapeutics Inc., Newton, MA; and., Byrne M; Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN., Villaume MT; Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN., Shaver AC; Department of Pathology, Microbiology and Immunology, and., Senapedis W; Karyopharm Therapeutics Inc., Newton, MA; and., Landesman Y; Karyopharm Therapeutics Inc., Newton, MA; and., Baloglu E; Karyopharm Therapeutics Inc., Newton, MA; and., Shacham S; Karyopharm Therapeutics Inc., Newton, MA; and., Savona MR; Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN.; Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN.
Publikováno v: Blood advances [Blood Adv] 2020 Feb 11; Vol. 4 (3), pp. 586-598.
Zobrazit plný text záznamu
8
Akademický článek
NL101 synergizes with the BCL-2 inhibitor venetoclax through PI3K-dependent suppression of c-Myc in acute myeloid leukaemia.
Autor: Lu, Ying1,2 (AUTHOR), Jiang, Xia1,2,3 (AUTHOR), Li, Youhong1,2,3 (AUTHOR), Li, Fenglin1,2 (AUTHOR), Zhao, Mengting3 (AUTHOR), Lin, Ye3 (AUTHOR), Jin, Lili1,2,3 (AUTHOR), Zhuang, Haihui1,2 (AUTHOR), Li, Shuangyue1,2 (AUTHOR), Ye, Peipei1,2 (AUTHOR), Pei, Renzhi1,2 (AUTHOR), Jin, Jie4 (AUTHOR), Jiang, Lei1,3 (AUTHOR) jianglei@nbu.edu.cn
Publikováno v: Journal of Translational Medicine. 9/27/2024, Vol. 22 Issue 1, p1-18. 18p.
Zobrazit plný text záznamu
9
Akademický článek
Novel--and Not So Novel--Inhibitors of the Multifunctional CRM1 Protein.
Autor: Aumann, Waitman K.1,2 waitman.aumann@emory.edu, Kazi, Rafi3, Harrington, Amanda M.4, Wechsler, Daniel S.1,2
Publikováno v: Oncology Reviews. 2024, p1-19. 19p.
Zobrazit plný text záznamu
10
Akademický článek
Vitamin K2 sensitizes the efficacy of venetoclax in acute myeloid leukemia by targeting the NOXA-MCL-1 pathway.
Autor: Tauchi, Tetsuzo1 (AUTHOR) tauchi144@gmail.com, Moriya, Shota2 (AUTHOR), Okabe, Seiichi3 (AUTHOR), Kazama, Hiromi2 (AUTHOR), Miyazawa, Keisuke2 (AUTHOR), Takano, Naoharu2 (AUTHOR) tauchi144@gmail.com
Publikováno v: PLoS ONE. 7/25/2024, Vol. 19 Issue 7, p1-19. 19p.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje